Life Sciences in 2030: A New Era for Biotechnology

26 May , 10:00–11:15
Technology for Leadership
Panel Session
Congress Centre, Conference Hall D4

Over the last five years, the world of biotechnology has witnessed a number of scientific breakthroughs in genetics and cell technologies, genome editing, targeted delivery of drugs and biopesticides, as well as 3D bioprinting of tissues and organs. The role of microbiota in human metabolism and life span has attracted a lot of attention. Innovations in biomedicine are at the forefront of the paradigm shift from treating disease to personalized health preservation. The global pharmaceutical and agricultural industries are moving towards increased investment in the development of innovative science-driven technologies, most of which are aimed at creating biotechnological products and methods. The growth in numbers of biotech patents is reaching 25–30% annually, and the global biotech market is forecast to grow by 160% between 2017 and 2030, ensuring that the investment attractiveness of biotechnology almost equals that of the IT sector. Meanwhile, recent biotech advances are provoking debates about IP protection, the need for investment, as well as regulatory and ethical aspects. How can the constant flow of new ideas and products be maintained? What is the future for intellectual property in healthcare and biotechnology? What new financial instruments are required to ensure sustainable growth in the field of research and development in Russia? How can a balance be maintained between the growing expenditure on R&D and optimization of government spending on healthcare and agriculture? What elements of state policy will play the biggest role in developing domestic R&D? What instruments should Russia use to stay competitive in the international biotech R&D market?

Andrey Sharonov, President, Moscow School of Management SKOLKOVO

Igor Drozdov, Chairman of the Board, Skolkovo Foundation
Sergei Kraevoi, Deputy Minister of Healthcare of the Russian Federation
Joerg Moeller, Corporate Executive Vice President, Member of the Executive Committee of Bayer AG's Pharmaceutical Division, Head of Global Development, Bayer AG
Meir Pugatch, Professor, University of Haifa
Alexey Repik, President, Delovaya Rossiya (Business Russia)
Dmitry Khalilov, Partner, Head of the Group for the Provision of Services to Enterprises of the Consumer Goods Sector, CIS, EY

Front row participants
Vadim Kukava, Executive Director, Association of Pharmaceutical Companies Innovative Pharma
Guzel Ulumbekova, President of the Board, Association of Medical Societies for Quality of Medical Care and Medical Education; Head, Higher School of Healthcare Organization and Management